↓ Skip to main content

Diagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer: a systematic review

Overview of attention for article published in Molecular Cancer, May 2016
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (71st percentile)
  • High Attention Score compared to outputs of the same age and source (92nd percentile)

Mentioned by

twitter
4 X users
patent
1 patent

Citations

dimensions_citation
84 Dimensions

Readers on

mendeley
172 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Diagnostic, prognostic and predictive value of cell-free miRNAs in prostate cancer: a systematic review
Published in
Molecular Cancer, May 2016
DOI 10.1186/s12943-016-0523-5
Pubmed ID
Authors

Edgars Endzeliņš, Vita Melne, Zane Kalniņa, Vilnis Lietuvietis, Una Riekstiņa, Alicia Llorente, Aija Linē

Abstract

Prostate cancer, the second most frequently diagnosed cancer in males worldwide, is estimated to be diagnosed in 1.1 million men per year. Introduction of PSA testing substantially improved early detection of prostate cancer, however it also led to overdiagnosis and subsequent overtreatment of patients with an indolent disease. Treatment outcome and management of prostate cancer could be improved by the development of non-invasive biomarker assays that aid in increasing the sensitivity and specificity of prostate cancer screening, help to distinguish aggressive from indolent disease and guide therapeutic decisions. Prostate cancer cells release miRNAs into the bloodstream, where they exist incorporated into ribonucleoprotein complexes or extracellular vesicles. Later, cell-free miRNAs have been found in various other biofluids. The initial RNA sequencing studies suggested that most of the circulating cell-free miRNAs in healthy individuals are derived from blood cells, while specific disease-associated miRNA signatures may appear in the circulation of patients affected with various diseases, including cancer. This raised a hope that cell-free miRNAs may serve as non-invasive biomarkers for prostate cancer. Indeed, a number of cell-free miRNAs that potentially may serve as diagnostic, prognostic or predictive biomarkers have been discovered in blood or other biofluids of prostate cancer patients and need to be validated in appropriately designed longitudinal studies and clinical trials. In this review, we systematically summarise studies investigating cell-free miRNAs in biofluids of prostate cancer patients and discuss the utility of the identified biomarkers in various clinical scenarios. Furthermore, we discuss the possible mechanisms of miRNA release into biofluids and outline the biological questions and technical challenges that have arisen from these studies.

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 172 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 <1%
Denmark 1 <1%
Belgium 1 <1%
Unknown 169 98%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 31 18%
Student > Master 24 14%
Researcher 23 13%
Student > Bachelor 18 10%
Other 10 6%
Other 33 19%
Unknown 33 19%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 54 31%
Medicine and Dentistry 44 26%
Agricultural and Biological Sciences 17 10%
Immunology and Microbiology 4 2%
Chemistry 3 2%
Other 10 6%
Unknown 40 23%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 May 2023.
All research outputs
#6,255,989
of 23,862,416 outputs
Outputs from Molecular Cancer
#447
of 1,795 outputs
Outputs of similar age
#95,751
of 338,580 outputs
Outputs of similar age from Molecular Cancer
#3
of 25 outputs
Altmetric has tracked 23,862,416 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 1,795 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 338,580 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 25 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 92% of its contemporaries.